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P E R S P E C T I V E
Regulatory Solutions to the Problem of High Generic
Drug Costs
Jing Luo, Ameet Sarpatwari, and Aaron S. Kesselheim
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston, Massachusetts
Recent reports have highlighted dramatic price increases for several older generic drugs, including a number of essential prod-
ucts used to treat deadly infectious diseases. Although most of these medicines have been widely available at reasonable prices
for decades, some manufacturers have seized on unique features of the pharmaceutical marketplace to seek substantial proﬁts.
In this Perspective, we examine limitations in current price regulation among public and private payors and consider several
reforms that could address the problem of expensive generic drugs through improved competition.
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Social media erupted in September 2015
with news of Turing’s 5000%markup of py-
rimethamine, a 62-year-old drug used to
treat toxoplasmosis. Overnight, the com-
pany’s brash founder and chief executive,
Martin Shkreli, became the poster child for
industry greed run amok. Turing’s action is
the latest in a series of astronomical increas-
es in the prices of select generic products.
Similar markups have been observed for
the antibiotic doxycycline (5000%, from
$0.06 to $3.36 per pill), the antiparasitic al-
bendazole (1900%, from $5.92 to $119.58
per typical daily dose), the antidepressant
clomipramine (3600%, from $0.22 to $8.32
per pill), and the heart failure drug digoxin
(900%, from $0.11 to $1.10 per pill)—to
name but a few [1, 2]. For patients using
these products, price increases translate
into greater out-of-pocket costs, decreased
adherence to medication regimens, and
worse health outcomes.
What’s to blame? Not patents—old
drugs such as pyrimethamine have long
since lost enforceable market exclusivity.
Instead, such price hikes emerge when
market forces result in limited competi-
tion among drug suppliers. Such an envi-
ronment can arise from consolidations or
manufacturers moving on to other prod-
ucts as in the case of digoxin, a generic
drug that used to be made by 8 generic
manufacturers but is now made by only
3. In the case of pyrimethamine, limited
competition had long existed, because
the drug was made for decades only by
GlaxoSmithKline, never attracting gener-
ic entrants because of its relatively small
sales. Still, it was sold at a modest price
(approximately $1 per pill). However,
GlaxoSmithKline sold the product in
2011 to a small, private business venture,
Amedra, which raised the price to $13.50
per pill before Turing acquired the rights
to the product in August 2015. There are
no federal or state laws that prevent such
price increases for prescription drugs; in-
deed, companies that naturally have or
acquire a monopoly may charge whatever
price they can get without fear of break-
ing antitrust laws.
The United States relies on market
forces to set prices, a mechanism that is
particularly ineffective when there is
only 1 manufacturer, as with pyrimeth-
amine. Even when multiple producers
of highly effective drugs for the same dis-
ease exist, as with direct-acting antivirals
used to treat hepatitis C, current laws re-
strict how much effect competition can
have on lower prices. The federal govern-
ment is statutorily prohibited from inﬂu-
encing negotiations between individual
Medicare Part D plan sponsors and drug
manufacturers. In part because of this
major limitation, a recent Department
of Health and Human Services Ofﬁce of
Inspector General report found that sav-
ings from these negotiations are substan-
tially less than savings obtained through
the Medicaid drug rebate program [3].
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Public payors are also restrained in their
abilities to use formularies to drive down
prices because of mandatory coverage re-
quirements [4]. Finally, state Medicaid
programs are supposed to obtain addi-
tional rebates when the price of brand-
name drugs rise faster than inﬂation,
but these statutory rebates will not apply
to generic drugs until 2017. [5].
For private payors, the competitive sit-
uation is not much better. Although com-
mercial health insurance plans may be able
to reduce costs by refusing to cover unrea-
sonably expensive generic drugs, many
plans may be reluctant to do so when the
offending drug is the ﬁrst-line treatment,
as pyrimethamine is for toxoplasmosis.
Some plans may elect to shift a greater
fraction of the costs to patients, but such
cost shifting can lead to ﬁnancial distress
and medication nonadherence. Although
some pharmaceutical manufacturers have
set up patient assistance programs to help
patients with insurance copays, these pro-
grams can have high qualiﬁcation hurdles
and are often time delimited. Even if pa-
tient assistance programs are effective, they
do not address substantial costs still paid
by the insurer, which are subsequently
transferred to all beneﬁciaries in the form
of higher premiums.
Some claim that a potential check on
skyrocketing generic drug prices is the
fact that other manufacturers could pro-
duce the same medicine at lower prices.
Unfortunately, the generic market is slow
to correct itself. All generic drugs marked
for sale must be reviewed and approved by
the US Food and Drug Administration
(FDA) for bioequivalence and manufac-
turing quality, but chronic underfunding
of the FDA Ofﬁce of Generic Drugs has
led to a 3-year-long queue before a generic
drug application gets reviewed. Legislation
instituting user-fee funding in 2012 sought
to ameliorate the problem but has not
shortened wait times to any signiﬁcant de-
gree yet. In addition, costs associated with
these fees may have the undesirable effect
of reducing incentives for competition
when the overall market is small. For ex-
ample, the current submission fee per
new generic drug application is $76 030.
An additional fee of $243 905 is charged
if FDA inspection is required at a new
manufacturing facility.
A variety of proposed solutions could
help the growing problem of expensive
generic drugs. Senator Bernie Sanders
and former Senator Hillary Clinton advo-
cate allowing the federal government to
negotiate Medicare Part D drug prices, a
power that the Veterans Health Ad-
ministration already enjoys. Clinton has
also called for better funding for the Of-
ﬁce of Generic Drugs and a $250 monthly
spending cap for patients, although a cap
alone would not shield payors from con-
tinuing to pay high prices and then pass-
ing them on to enrollees or taxpayers.
Another essential way to tackle rising
generic drug prices is by fostering greater
market competition. The government—
perhaps the Centers for Medicare &
Medicaid Services (CMS)—could better
monitor the generic drug marketplace to
ensure a minimum number of manufac-
turers of essential medicines. Previous re-
search suggests that adequate generic
prices can be maintained with 4 or more
producers [6]. When the threat of falling
below this threshold emerges, CMS could
work with the FDA to allow temporary im-
portation of products by manufacturers
vetted by stringent regulatory authorities
around the world. An expedited review
process could be created for approval of
new generic drug applications that address
an important public health need. This pro-
cess could be modeled after the numerous
expedited review pathways that exist for
brand-name drugs. To incentivize new en-
trants into a ﬂagging market, the FDA
could also waive generic drug user fees.
Although all of these measures would like-
ly require Congressional authorization,
broad bipartisan support exists among
the electorate to change the status quo.
More than 85% of the 4 billion annual
prescriptions in the United States are
ﬁlled with generic drugs. When the sys-
tem works, the use of generics has gener-
ated large cost-savings for patients and
payors, increased medication adherence,
and improved public health. However,
for cases in which companies have driven
up the price of drugs simply because they
can, a strategy must be developed that
helps patients access needed medications
as quickly, affordably, and safely as possi-
ble. Although public shaming can play a
role—as it did in prompting Shkreli to re-
consider the price of pyrimethamine—a
comprehensive plan is needed to address
the other cases and help prevent future
crises from emerging.
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